Reimbursement review

On the 1st of October, 2002 a new Act (2002:160) on Pharmaceutical Benefits etc. entered into force. The medicines which before the 1st of October 2002 were on the accepted list of medicines for reimbursement were also then covered by the pharmaceutical reimbursement system. We are reviewing all pharmaceuticals which had been eligible for reimbursement according to the old system.

It was not practically possible in the transition to the new system to test these pharmaceuticals against the new criteria for reimbursement. The medicines present in the system then were therefore automatically granted eligibility for reimbursement even though in some cases they may not have fulfilled the criteria demanded of them.

It is the TLV who decides if a new medicine should be granted reimbursement status. The board also has the task of reviewing the entire list of eligible pharmaceuticals from the time of the Act coming into effect to ascertain the fulfillment of the criteria for reimbursement for each medicine in question.

This means going through approximately 2 000 pharmaceuticals altogether and taking a decision on their continued inclusion or not in the pharmaceutical reimbursement system.

You will find documents regarding the reimbursement review under Completed reviews.